Cargando…

Primary treatment of diabetic macular edema

Diabetic macular edema (DME) is a leading cause of vision loss in older Americans. Thermal laser treatment remains the mainstay of treatment for DME. Recently, alternative primary treatments for DME have been evaluated. These treatments include intravitreal injections of steroids as well as pharmace...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranchod, Tushar M, Fine, Stuart L
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685231/
https://www.ncbi.nlm.nih.gov/pubmed/19503772
_version_ 1782167304164868096
author Ranchod, Tushar M
Fine, Stuart L
author_facet Ranchod, Tushar M
Fine, Stuart L
author_sort Ranchod, Tushar M
collection PubMed
description Diabetic macular edema (DME) is a leading cause of vision loss in older Americans. Thermal laser treatment remains the mainstay of treatment for DME. Recently, alternative primary treatments for DME have been evaluated. These treatments include intravitreal injections of steroids as well as pharmaceuticals containing antibodies against vascular endothelial growth factor (VEGF). Surgical treatment has been shown to be appropriate in selected cases. We review the evidence and scientific rationale for various primary treatment options in patients with DME. Regular and timely ophthalmologic evaluation remains crucial to recognition and treatment of macular edema in diabetic patients.
format Text
id pubmed-2685231
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26852312009-06-05 Primary treatment of diabetic macular edema Ranchod, Tushar M Fine, Stuart L Clin Interv Aging Review Diabetic macular edema (DME) is a leading cause of vision loss in older Americans. Thermal laser treatment remains the mainstay of treatment for DME. Recently, alternative primary treatments for DME have been evaluated. These treatments include intravitreal injections of steroids as well as pharmaceuticals containing antibodies against vascular endothelial growth factor (VEGF). Surgical treatment has been shown to be appropriate in selected cases. We review the evidence and scientific rationale for various primary treatment options in patients with DME. Regular and timely ophthalmologic evaluation remains crucial to recognition and treatment of macular edema in diabetic patients. Dove Medical Press 2009 2009-05-14 /pmc/articles/PMC2685231/ /pubmed/19503772 Text en © 2009 Ranchod and Fine, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Ranchod, Tushar M
Fine, Stuart L
Primary treatment of diabetic macular edema
title Primary treatment of diabetic macular edema
title_full Primary treatment of diabetic macular edema
title_fullStr Primary treatment of diabetic macular edema
title_full_unstemmed Primary treatment of diabetic macular edema
title_short Primary treatment of diabetic macular edema
title_sort primary treatment of diabetic macular edema
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685231/
https://www.ncbi.nlm.nih.gov/pubmed/19503772
work_keys_str_mv AT ranchodtusharm primarytreatmentofdiabeticmacularedema
AT finestuartl primarytreatmentofdiabeticmacularedema